
Eli Lilly Revenue Surges 45% in 2025 as GLP-1 Drugs Drive Record Sales
Eli Lilly and Company reported record financial results in 2025, with total revenue rising 45% year over year to $65.18 billion, up from $45.04 billion in 2024, driven by continued demand for its GLP-1 diabetes and obesity treatments. The company’s



























